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Developing vehicles for the delivery of therapeutic molecules, like siRNA, is an area of active research. Nanoparticles composed
of bovine serum albumin, stabilized via the adsorption of poly-L-lysine (PLL), have been shown to be potentially inert drug-
delivery vehicles. With the primary goal of reducing nonspecific protein adsorption, the eﬀect of using comb-type structures of
poly(ethylene glycol) (1 kDa, PEG) units conjugated to PLL (4.2 and 24 kDa) on BSA-NP properties, apparent siRNA release rate,
cell viability, and cell uptake were evaluated. PEGylated PLL coatings resulted in NPs with ζ-potentials close to neutral. Incubation
with platelet-poor plasma showed the composition of the adsorbed proteome was similar for all systems. siRNA was eﬀectively
encapsulated and released in a sustained manner from all NPs. With 4.2 kDa PLL, cellular uptake was not aﬀected by the presence
of PEG, but PEG coating inhibited uptake with 24 kDa PLLNPs.Moreover, 24 kDa PLL systems were cytotoxic and this cytotoxicity
was diminished upon PEG incorporation. The overall results identified a BSA-NP coating structure that provided eﬀective siRNA
encapsulation while reducing ζ-potential, protein adsorption, and cytotoxicity, necessary attributes for in vivo application of drug-
delivery vehicles.
1. Introduction
Short interfering RNA (siRNA) is extremely promising for
the therapeutic treatment of a myriad of diseases; however,
its clinical application has hitherto been hindered by an
apparent inability to control its delivery. The use of NP
based drug delivery vehicles presents several advantages over
conventional delivery stratagems, including the fact that they
may be used for precise tissue targeting, remain in blood
for a prolonged time, and be immediately injected into the
systemic circulation. Furthermore, favorable tissue responses
have been observed for decreasing particle sizes [1] and a
multitude of covalent and noncovalent modifications of NP
surfaces can be achieved, aspects that facilitate the design of
more eﬀective carriers. In particular, BSA-based NPs have
many advantageous qualities [2]: presence of a hydrophobic
core facilitating delivery of hydrophobic drugs, a natural
abundance in plasma, relative stability and inertness in
biochemical pathways, availability, and a relatively benign in
vivo biological fate [3]. Unlike NPs fabricated from synthetic
polymers, it is thought that the natural protein removal
mechanisms will result in a reduced overall toxicity related
to the application of BSA NPs [3]. That said, an important
step in facilitating the localization of these NPs at the site
of interest involves both decreasing their removal from the
circulation (i.e., decreasing opsonization) as well as ensuring
that any targeting moiety remains able to interact with
the cellular site of interest. Inhibiting nonspecific protein
adsorption will then be central to both of these eﬀects.
A common strategy for preventing protein adsorption at
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the tissue-material interface is to incorporate end-tethered
PEG to the surfaces of biomaterials. It has been well estab-
lished that the presence of end-tethered PEG can prevent
particulate aggregation, reduce interactions with plasma
proteins [4], minimize reticuloendothelial system clearance,
and prolong blood circulation time of a host of NPs [5–7].
PEGylation of surfaces has been shown to impede non-
specific protein adsorption [8], where both the presence
and conformation of end-tethered PEG play a critical role
[9, 10]. It is noteworthy that not only is the amount of
plasma protein adsorbed at the tissue-biomaterial interface
important in obfuscating an engineered surface but also the
composition of the protein layer itself is critical, as this may
ultimately direct host responses. NP opsonization has been
correlated to surface properties, including hydrophilicity,
roughness, ζ-potential, and surface chemistry [11]. Recent
results [12] have shown that systemic administration of
BSA NPs, stabilized with polyethyleneimine-graft-PEG with
bisphosphonic acid attached for bone targeting, showed
no beneficial eﬀects associated with the polymer coating.
Although the reason for this result was not fully elucidated,
it was postulated that the biodistribution of the NPs may be
aﬀected by the presence of the adsorbed protein corona to
the PEG modified NPs; it is hoped that further analyzing
the adsorbed protein composition to these PEG modified
BSA NPs may clarify this point. Other previous work [13]
has looked specifically at the use of positively charged poly-
L-lysine (PLL) as a coating polymer that stabilizes the NP
used for the apparent release of siRNA from BSA NPs. It
was observed that, for low concentrations of PLL, varying
the size of the PLL used for coating resulted in minimal
eﬀect on the net release of siRNA from the NPs. In further
work [14], the release of a model drug from BSA NPs could
be controlled from ∼5 to 90% over 14 days, depending on
the nature of coating designed to display diﬀerential stability
against endogenous enzymes.
In this study, we continued the development of BSA NPs
by exploring the role of PEG coating by employing comblike
structures of PEG-conjugated PLLs and compared systems
stabilized via unmodified PLL. Specifically, PLLs of 4.2 and
24 kDa were utilized to understand the eﬀect molecular
weight may have on critical issues related to NP stabilization,
siRNA encapsulation and passive release kinetics, plasma
protein adsorption, cytotoxicity, and cellular incorporation.
Conjugates of PLLs with 1 kDa PEG were synthesized so as
to determine if any direct eﬀect on NP stabilization as well
as siRNA encapsulation and passive release kinetics might
be altered. The cellular uptake of the NPs and the plasma
protein adsorption profile were assessed, investigating the
role of PEG coating on these features. Our results identified
specific types of BSA NPs that provided adequate siRNA
release and cellular uptake with relatively low amounts of
protein adsorption and cytotoxicity.
2. Materials and Methods
BSA and HBr salt of PLLs of diﬀerent MWs (4.2 and 24 kDa)
were purchased from Sigma-Aldrich (St. Louis, MO, USA)
and used without further purification. The sodium dodecyl
sulfate (SDS) was obtained from J. T. Baker (Phillipsburg,
NJ, USA). FAM-labelled siRNA (double stranded, 21 base
pairs) was purchased from Ambion Inc. (Austin, TX, USA).
EDTA/trypsin (10X; Invitrogen, Carlsbad, CA, USA) was
diluted 1 : 10 with Hank’s Buﬀered Salt Solution (HBSS;
Invitrogen) to 0.05 g/L concentration before use. Dulbecco’s
Modified Eagle Medium (DMEM; high glucose), and pen-
icillin/streptomycin (10000U/mL/10mg/mL) solution were
obtained from Invitrogen. Fetal bovine serum (FBS) was
from PAA Laboratories (Etobicoke, Ontario, Canada). So-
dium phosphate, monobasic, monohydrate sodium phos-
phate, and sodium chloride laboratory-grade reagents were
purchased from EMD Chemical Inc. (Darmstadt, Germany).
Ethanol was purchased from Fischer Scientific (Ottawa, On-
tario, Canada). The N-hydroxysuccinimide ester of 1 kDa
(mPEG-NHS) was obtained from Creative PEG works, NC,
USA. The 3,3′,5,5′-tetramethylbenzidine substrate (TMBS)
was obtained from Promega (Madison, WI, USA). The
dialysis tubing of various MW cutoﬀs was obtained from
Spectrum Laboratories Inc. (Rancho Dominguez, CA, USA).
2.1. PEG Conjugation to PLL. Previously reported methods
were used to conjugate PLL to 1 kDa PEG [15]. Briefly, PLL
was dissolved in 0.1M phosphate buﬀer (PB, pH 7.4) to a
final concentration of 2.4mg/mL. mPEG-NHS was diluted
to 18mM using 0.1M PB, added to the PLL solution, and
reacted for 3 hrs at room temperature. Solution was dialyzed
2 days againstMilliQ (18Ω) water, at 4◦C;MilliQ water being
changed twice a day. Dialysate containing 4.2 and 24 kDa
PLL was freeze-dried and used to reconstitute the polymer
solutions at desired concentrations.
2.2. NP Preparation. BSA NPs were formed via a coacerva-
tion method as detailed elsewhere [13]. Briefly, 250 μL of
10mg/mL BSA in water was added dropwise to an equal
volume of 10mMNaCl in water at room temperature. After
15min stirring (600 rpm, room temperature), ethanol was
added dropwise to a final volume ratio of 6 : 1, ethanol to
BSA solution. The mixture was stirred for 3 hrs to form NPs.
To stabilize formed NPs, native PLLs (0.3mg/mL) or PEG-
conjugated PLLs (0.3mg PLL equivalents/mL) in deionized
water were introduced dropwise to the equal volume of NPs
suspension under constant stirring. Stirring was continued
for 1 hr at room temperature to ensure time for the PLL
and PEG-PLL conjugates to adsorb to the BSA NP surface.
Suspensions of coated NPs were dialyzed against ddH2O
for 3 days (12 hrs between solution replacements). Where
indicated, the amount of coating on the surface was deter-
mined by using the FITC-labeled PLL or PEG-PLL. The poly-
mer labeling was achieved by incubating 10 μL of 0.1mM
FITC solution (in DMSO) with 1mL of PLL or PEG-PLL
(2mg/mL in 100mM phosphate buﬀer, pH = 7.4) for 1 hr
at room temperature. Ethanol (9mL) was then added to this
solution. The solution then was centrifuged at room tem-
perature (3000 rpm) for 15 minutes, and the supernatant,
with unconjugated FITC, was removed. The pellet formed
during this process was further washed with 5mL of ethanol
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and centrifuged at 3000 rpm for 15min [13]. The solids
obtained were air-dried under vacuum for 5 hrs and stored
in the dark at 4◦C until used. The coating of FITC-labeled
polymer was determined using fluorescence measurements.
The coated NPs suspension was then diluted with phosphate
buﬀer (pH = 7.4) by 100% and centrifuged (15,000 rpm,
1 hr) and fluorescence (λEX: 485 nm; λEM: 527 nm) of the
supernatant was analyzed using a multiwall plate reader
(Thermo Labsystems, Franklin, MA, USA). A calibration
curve generated was used to calculate the coating eﬃciency
as (1 − FITC-polymersupernatant/(FITC-polymersupernatant +
FITC-polymerpellet))× 100%.
2.3. Particle Sizing and ζ-Potential. Mean particle size of the
coated and uncoated NPs were determined using dynamic
light scattering (Zetasizer 3000 HS, Malvern Instruments
Ltd., UK) with a 633 nm He-Ne laser at a scattering angle
of 90◦. Uncoated BSA NPs were used directly for the
measurements while the coated BSA NPs were diluted 1 : 2
with PB (10mM, pH 7.4). Intensity measurements were
used to determine the NP size. The ζ-potential of the NPs
was determined by measuring their electrophoretic mobility
using the same instrument at 25◦C.
2.4. Plasma Incubation and Elution. Human blood plasma
was obtained from Canadian Blood Services, where Cana-
dian Blood Services obtained written informed consent
from all volunteers for the collection and distribution of
human blood products for research purposes. Human blood
products were then shipped to our lab and used following
research ethics procedures as approved by the University
of Alberta Research Ethics Board (Institutional), Canadian
Blood Services Research Ethics Board (Federal), and the
National Research Council of Canada Research Ethics Board
(Federal). NP solutions (500 μL) were combined with an
equal volume of undiluted human plasma and incubated at
room temperature for 2 hrs with gentle rocking. The samples
were then centrifuged at 13000 rpm for 10 minutes and the
supernatants discarded. Pellets were resolubilized in 1mL
of 0.15M phosphate buﬀered saline (PBS; pH 7.4) for 30
minutes and the procedure was repeated two times. These
samples were spun down and pellets were solubilized in 2%
w/v SDS in 0.15M PBS for one hr, with rocking at room
temperature in order to elute adsorbed plasma proteins.
To separate the NPs from the eluted plasma proteins, the
samples were centrifuged at 13000 rpm for 10 minutes and
the supernatants collected and characterized using SDS-
PAGE and immunoblotting analysis.
2.5. SDS-PAGE and Immunoblotting. Reduced SDS-PAGE
and immunoblotting techniques were used to evaluate and
to identify eluted proteins as described previously [9]. All
electrophoretic apparatus were purchased from Bio-Rad
(Hercules, CA). Briefly, samples were separated on 12% SDS-
PAGE gels and then transferred onto a 0.2 μm immunoblot
PVDF membrane. The membrane was cut into strips for
total protein staining using colloidal gold (Bio-Rad) and
for immunoblotting. Primary and secondary antibodies (see
Table S1 in Supplementary Materials available online at
doi:10.1155/2012/584060) were used without further purifi-
cation at concentrations of 1 : 1000. To visualize protein-
antibody complexes, 350 μL of stabilized TMBS substrate was
incubated with membrane strips for 10 minutes at room
temperature, with rocking. The colour-developing reaction
was then quenched for 10 minutes using 2mL of MilliQ
water.
2.6. Preparation of siRNA Loaded BSA NPs and Release Stud-
ies. The coacervation technique previously described was
employed to prepare BSA NPs encapsulating siRNA. Briefly,
500 μL of aqueous solution of BSA (10mg/mL) was added
to an equal volume of 10mMNaCl solution under stirring
(600 rpm) in glass vials. The stirring was continued for 15
minutes at room temperature. To achieve siRNA encapsu-
lation, siRNA solution (20 μL of 0.15mg/mL) was added to
this binary solution and stirred at 600 rpm for 1 hr at room
temperature. The siRNA (scrambled) used for encapsulation
was either unlabeled or labeled with FAM. NPs were then
formed by adding ethanol dropwise (final volume ratio of
ethanol to starting BSA solution = 6). Stirring was continued
for 3 hrs at room temperature after the complete addition
of ethanol. To coat these siRNA loaded BSA NPs with PLL’s,
500 μL of an aqueous polymer solution was added dropwise
to an equal volume of BSA NPs suspension under constant
shaking of 500 rpm. Shaking was continued for 1 hr.
To obtain encapsulation eﬃciency, NPs containing FAM-
labeled siRNA were centrifuged at 15000 rpm for 30 minutes.
The FAM-labeled siRNA in the supernatant and pellet
were determined using a plate reader (λEX: 485 nm, λEM:
527 nm) and a calibration curve based on known concen-
trations of FAM-labeled siRNA. The encapsulation eﬃciency
was calculated as (FAM-siRNApellet/(FAM-siRNApellet +
FAM-siRNAsupernatant))× 100%. FAM-labeled siRNA was
also used to study the apparent release kinetics of siRNA from
BSA NPs coated with diﬀerent polymers. Polymer concen-
tration of 0.3mg/mL was used to coat BSA NPs and release
values were normalized to 0% for day 0, as described previ-
ously [13]. The suspensions were incubated at 37◦C in PBS
under shaking and aliquots were taken at predetermined time
points and centrifuged at 15000 rpm for 30 minutes. The
siRNA in the supernatant and pellet were determined using
a calibration curve.
2.7. Cell Uptake Studies. To assess cellular uptake of NPs,
human breast cancer MDA-231 cells were used. Two sets
of NPs were prepared for cell uptake; (i) uncoated and
coated BSA NPs with no siRNA, and (ii) uncoated and
coated BSANPs loaded with FAM-labeled siRNA. The siRNA
encapsulation was achieved as described above, except that
20 μL of siRNA solution (0.15mg/mL) was used for FAM-
labeled siRNA encapsulation. 1000 μL of aqueous polymer
solution was added to 2000 μL of BSA NPs suspension (final
concentration: 0.3mg/mL) under shaking for 1 hr to achieve
coating. The suspensions were then dialyzed against DMEM
for 24 hrs with two changes in dialysis solution.
For uptake, a monolayer of MDA-MB-231 cells were
seeded in 24-well plates and allowed to attach for 24 hrs
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Table 1: Selected characteristics of prepared NPs: (i) eﬃciency of PLL and PEG-PLL coating on BSA NPs, (ii) ζ-potential, and (iii) average
size (average ± standard deviation, n ≥ 5). Note that the NPs from 4.2 kDa PLL-PEG coating gave two size populations with relative ratios
of 14% and 86%.
Coated amount (mg conjugate/mg BSA) ζ-Potential (mV) Diameter (nm)
Uncoated — −10.1± 0.4 255± 30
4.2 kDa PLL 0.12± 0.03 10.1± 0.5 350± 90
24 kDa PLL 0.10± 0.02 20.4± 0.5 310± 30
4.2 kDa PEG-PLL 0.016± 0.006 1.8± 0.3 220± 26 (14%)
880± 100 (86%)
24 kDa PEG-PLL 0.007± 0.003 7.8± 0.9 845± 140
to reach ∼50% confluency (see [16] for culture conditions
on the cells). The medium was replaced with 500 μL of
fresh DMEM with 10% FBS and 1% antibiotics (peni-
cillin/streptomycin). Then, 500 μL of NP suspension in
DMEM was added to the cells (in triplicate) and the
cells were incubated for 24 hrs at 37◦C in a humidified
atmosphere of 95% air/5%CO2. After the incubation period,
cells were washed with HBSS (×2) and trypsinized. A 3.7%
formaldehyde solution was added to suspended cells and
the siRNA uptake was quantified by a Beckman Coulter
QUANTA SC flow cytometer using the FL1 channel to detect
cell-associated fluorescence. The percentage of cells showing
FAM-fluorescence and the mean fluorescence in total cell
population were determined. Calibration was performed by
gating with the negative control (i.e., “No Treatment”) group
such that the autofluorescent cell population represented 1-
2% of the total cell population.
3. Results and Discussion
The nature of the NP coating, in addition to its role in NP
stabilization, is expected to control the apparent release of the
encapsulated therapeutic agents whilst creating an interface
that inhibits nonspecific protein adsorption. In addition to
this, it is desirable to evaluate if PEGylation of the PLL
based NP coating aﬀects cytotoxicity and/or the cellular
uptake of siRNA. Towards this end, NPs were coated with
4.2 and 24 kDa PLLs and PEG conjugates of the same. The
use of PLL was considered advantageous as compared to
previously employed PEI since the latter is synthetic, highly
cytotoxic to mammalian cells, and undergoes an ill-defined
degradation pattern. Unlike chemical crosslinkers, such as
glutaraldehyde, the coating approach employed is thought to
be a more bioacceptable means to stabilize the particles and
further provides a convenient means of surface control. After
characterization of the NP features, protein adsorption, com-
position of adsorbed protein layer, apparent siRNA release,
cytotoxicity, and cellular uptake of siRNA were assessed.
3.1. PEG-PLL Conjugation. Conjugation of mPEG-NHS to
PLL was demonstrated through the addition of varying
quantities of PEG and subsequent NMR analysis after
dialysis to determine the resulting PEG:PLL molar ratio. The
maximum conjugation ratio of PEG : PLL was determined to
be ∼26 and 150 for 4.2 and 24 kDa PLL systems, respectively
(results not shown). On average, this translated into the
incorporation of ∼6 PEG per 1 kDa of PLL for both 4.2 and
24 kDa systems. However, given that the PDI of the PLL and
PEG polymer was not one, these values are considered on
average.
3.2. NP Characterization. The amount of PLL or PEG-PLL
incorporated into the coating used to stabilize the NPs was
determined so as to evaluate the eﬀect of the presence of PEG
upon ζ-potential and resulting NP size. It was evident that
unmodified PLLs, regardless of size, incorporated similar
mass amounts into the NP coating layer of ∼0.1mg PLL
per mg BSA (Table 1). Although, it is evident that on a
mole basis there would be more molecules of 4.2 kDa PLL
adsorbed than 24 kDa systems, PLL adsorption is largely
driven by electrostatic forces so the amount of PLL needed
to occupy the charges on the surface of the NP was similar,
regardless of individual chain lengths.Moreover, this amount
of PLL in the coating layer agreed with previously published
results for similar systems [13]. However, PEGylated 4.2
and 24 kDa PLL systems showed an adsorbed amount of
PEG-PLL at 16 ± 6 and 7 ± 3 μg conjugate per mg BSA,
respectively. An order of magnitude decrease in adsorbed
mass was seen in the stabilizing layer upon PLL PEGylation.
It is likely that this significant decrease in adsorbed mass
was due to steric hindrances imposed by preadsorbed PEG
conjugates that prevented other PEG-PLLs from reaching the
interface or from the screening of PLL charges that would
reduce the driving force for PEG-PLL incorporation into
the film. Diﬀerences observed between 4.2 and 24 kDa PEG-
PLL coatings suggest that the smaller polymer conjugate may
better fill the surface of the NP.
Mean particle sizes and ζ-potentials for PLL-coated NPs
were similar to previously reported values (Table 1) [13]. NPs
formed with 4.2 and 24 kDa PLLs yielded statistically similar
average particle sizes of ∼350 and 310 nm, respectively;
results similar to previously reported values for PLL coated
BSA NPs [13]. Upon using PEG-PLL for stabilizing the
BSA NPs, the diameter of the NPs increased dramatically.
For 4.2 kDa PEG-PLL systems a bimodal distribution in
particle diameter was observed, where ∼14 and 86% of
the NP population had diameters of ∼220 and 880 nm,
respectively. Systems composed of 24 kDa PEG-PLL systems
had an average diameter of ∼845 nm. While the diﬀerence
between systems using diﬀerent PLLMWswas negligible, it is
obvious that the diﬀerences observed upon incorporation of
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Table 2: BSA NP plasma adsorption conditions and results as evaluated with immunoblots.
Fragment size (kDa) Fragment name
System
4.2 PLL 24 PLL 4.2 PEG-PLL 24 PEG-PLL
Fibrinogen
48 γ ∗∗∗ ∗∗ ∗∗ ∗∗∗
56 β ∗∗∗ ∗∗ ∗∗∗ ∗∗∗
68 α ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗
<48 Cleavage ∗ 0 ∗ ∗∗
Albumin 66 ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗
C3
42 Activation ∗∗ ∗ ∗∗ ∗∗
70 β ∗ ∗∗ ∗∗ ∗∗
115 α 0 0 0 0
Apolipoprotein A-1 27 0+ 0+ 0 0
Plasminogen
25 0 0 0 0
60 0+ ∗ 0 0
Plasma proteins eluted with 1.0mL of 2% SDS in PBS; 0 indicates zero band intensity, while 0+ indicates trace band intensity and ∗∗∗indicates highest
intensity bands. Proteins shown in Table 1 but absent from this table were not observed in immunoblotting (zero band intensity throughout).
PEG were not. This large diﬀerence may be a direct result of
the steric hindrances imposed by adsorbed PEG-PLL leading
to lower amount of conjugate being incorporated into the
stabilizing coating. With less conjugated PEG-PLL filling the
surface, a larger NP may form.
The ζ-potentials of all four types of NPs were positive,
suggesting suﬃcient PLL or PEG-PLL adsorbed to oﬀset
the inherent negative ζ-potential of the BSA NP. The ζ-
potential for the 4.2 and 24 kDa PLL systems were ∼10
and 20mV, respectively. The ζ-potentials for similar systems
were found to plateau, with respect to increasing PLL
concentration, around these values, suggesting that the NP
surfaces were nearly saturated [13]. The PEG-PLL coating
instead appeared to reduce the ζ-potential, as the 4.2 and
24 kDa PEG-PLL constructs had ζ-potentials of ∼1.8 and
7.8mV, respectively. Low average ζ-potentials for the PEG-
PLL coated NPs seemed to suggest the presence of PEG,
as PEG should result in a less charged surface as well as
possibly screening ζ-potentials. It is interesting that there
was a higher ζ-potential for the 24 versus 4.2 kDa PEG-PLL
system given that the 4.2 kDa system adsorbed more PEG-
PLL material. It may be that the more 4.2 kDa PEG-PLL
molecules result in a more compressed PEG layer that shields
the ζ-potentials of the PLL and thus lower the ζ-potential.
Whereas the 24 kDa PEG-PLL film has more flexible PEG
chains (i.e., mushroom regime) that may allow for more of
the ζ-potential to be measured. The literature has shown that
PEI-PEG systems observed a ζ-potential plateau at ∼14mV,
which was greater than that observed herein [12]. A weak
positive charge (ζ-potential < +5mV) has been suggested for
minimally adsorbing surfaces [17, 18] and PEG-coated NPs
prepared in this study fulfill this feature, and surface PEGs
could further improve the stability for such low ζ-potential
NPs. Moreover, this low ζ-potential may also mediate NP
aggregation; however, previous studies have shown that NP
sizes are highly dependent on coating properties [13].
3.3. Protein Adsorption to NP Systems. The adsorption of
proteins at the NP-blood interface is crucial to several
important aspects of drug delivery, where a decrease in the
amount of adsorbed protein may lead to an increase in the
eﬀectiveness of incorporating tethered targeting molecules
on the NP surface. Moreover, decreasing protein adsorption
may lead to increased circulation times by decreasing opson-
ization and potential host responses to the NP. Thus, in order
to understand how the diﬀerences in the coating aﬀects both
nonspecific protein adsorption as well as the composition
of the adsorbed layer, 4.2 and 24 kDa PLL and PEGylated
versions of these PLLs were evaluated using platelet poor
plasma adsorption, where adsorbed proteins were eluted
from the surface using a 2% SDS incubation. As there is
no way to accurately control the total surface area of NPs
in solution, or to accurately estimate it, conducting a total
protein analysis would not be indicative of the amount of
adsorbed protein per surface area. Moreover, as it has been
shown previously that 4.2 and 24 kDa PLL systems do not
leak more than 1% of the BSA incorporated into the formed
NPs within 2 hrs, all eluted proteins are most likely from
adsorbed protein [13].
Since immunoblot analysis is qualitative for detecting
protein levels, and more informative for determining protein
presence, equal volumes of eluted protein solution were
loaded (50 μL), being a commonly employed technique. The
results of the immunoblot analysis for the adsorbed plasma
proteins on NPs are summarized in Table 2. The presence of
high levels of fibrinogen and fibrinogen fragments suggests
active coagulation in all samples except for the 24 kDa PLL
NPs. It is possible that fibrinogen might have been less
easily eluted from these surfaces. Adsorbed fibrinogen has
previously been shown to activate platelets and induce the
accumulation of phagocytes [19, 20].
High intensity bands for human serum BSA were ob-
served for all formulations. BSA adsorption in these systems
is not unusual as the surfaces were formedwith polymers that
bind avidly to BSA. BSA is an unreactive protein that displays
anticell adhesion and provides “passivation” properties, so
that the presence of BSA in such great quantities on all of
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the NP systems is promising from a biocompatibility stand-
point [21, 22].
Complement activation is a response against foreign sur-
faces with important implications for biocompatibility of
administered agents [23]. Complement activation pathways
are triggered by a variety of stimuli but ultimately serve to
cause opsonization through the activation of C3 [24]. C3
is composed of α (115 kDa) and β (70 kDa) peptide chains.
If complement is activated and the C3 cleaved, a 42-kDa
fragment is created. The 42 kDa C3 fragment and the 70-
kDa β-fragment were both present in relatively significant
quantities on all NP systems. The presence of the 42-kDa C3
fragment indicated complement activation. PLL-coated NPs
appeared to adsorb less 70 kDa C3. While this may be the
case, it is important to consider that 70 kDa C3 may simply
be less readily eluted from these surfaces than the others.
The 115-kDa α C3 fragment was not observed on any of the
systems. It is possible that the NPs did generate this fragment,
but it did not adsorb to the NP surfaces.
Trace levels of apolipoprotein A-1 were found on both
PLL-coated NP systems, while none was observed on PEG-
PLL coated NPs. The presence of apolipoprotein A-1 implies
anti-inflammatory activity. The literature states that HDLs
such as apolipoprotein A-1 are also capable of endothelial
protection, including the control of cell proliferation, the
inhibition of apoptosis, the modulation of the secretory
functions, the regulation of coagulation, fibrinolysis, and
platelet adhesion, and the inhibition of inflammatory pro-
cesses. Similar to the apolipoprotein A-1 case, 60 kDa plas-
minogen was found in moderate quantities on the 24 kDa
PLL system, with minor amounts in 4.2 kDa PLL coated
NPs and none on PEG-PLL coated NPs. This data suggests
that PEG can eﬀectively block plasminogen adsorption in
these NP systems. Plasminogen binding is likely to be
facilitated due to the epsilon amines of the PLL chains [25].
The presence of surface-localized plasminogen may actually
enhance the biocompatibility characteristics of the NPs, as
it is the precursor for plasmin, which has the potential for
clot dissolution [25]. Further studies are needed to discern if
the surface-adsorbed plasminogen indeed can be converted
to plasmin within blood while localized to the NP surface.
In addition to these five proteins, sixteen other proteins
were screened without detection, even in trace amounts,
for any of the NP formulations. These fifteen include
high molecular weight kininogen (HMWK), low molecu-
lar weight kininogen (LMWK), factor I, fibronectin, α1-
antitrypsin, thrombin, prothrombin, protein C, vitronectin,
protein S, prekallikrein, antithrombin, immunoglobulin G
(IgG), factor XII, factor XI, and α2-macroglobulin. The
lack of the contact phase coagulation proteins of the
intrinsic clotting cascade, prekallikrein, HMWK, factor XI
and factor XII (Table 2) implied that the NPs should not
be procoagulant. HMWK has been shown to both enhance
biocompatibility through its anticell adhesion properties, as
well as to hinder it by acting as a cofactor for the contact
phase of coagulation; therefore, it is unclear whether the
presence of this protein on the surfaces is desirable [26,
27]. Further along the cascade, the absence of prothrombin
and thrombin reinforces the inference that the systems are
noncoagulant [28]. Fibrinogen was detected in significant
quantities (Table 2), so the absence of thrombin is especially
important to prevent fibrin formation.
The anticoagulation pathway was also monitored via the
immunoblots. Protein C, a significant component of an-
ticoagulation, was not observed in significant quantities.
Protein S, a cofactor for Protein C, and vitronectin, an in-
direct inhibitor of plasminogen conversion to plasmin, were
also not detected, indicating that the proteins controlling
anticoagulation were not present. Two proteins involved in
both coagulation and anticoagulation pathways, α2-ma-
croglobulin and antithrombin, were investigated, but not
detected again. Antithrombin is an uncharged serine pro-
tease inhibitor that is responsible for limiting irregular
clotting [28]. Due to the absence of thrombin, the absence
of α2-macroglobulin is inconsequential for the coagulation
pathway. α2-Macroglobulin inhibits plasmin in the anticoag-
ulation pathway, but was not detected. Antithrombin, which
has a variety of targets in both the coagulation and anticoag-
ulation pathways, was not observed in any of the NP systems.
The absence of other proteins not involved in clotting or
fibrinolysis cascades is informative. Lack of IgG adsorption
suggests a lack of reactivity by the circulating antibodies and
no subsequent stimulation of the immune response. The lack
of IgG also indicates that the possible complement activation
seen (based on the presence of C3 fragments; Table 2) occurs
via the alternative pathway only. The α1-antitrypsin is an
important serine proteases in the body [29]. α1-Antitrypsin
has a charge of −12 at a pH of 7.0, so its adsorption to the
positively charged NPs would be expected. However, it was
not detected in the immunoblot analysis. It is possible that
other negatively charged proteins are preferentially adsorbed
to the surface of the NPs, neutralizing its charge.
3.4. siRNA Encapsulation Eﬃciency and Release. siRNA en-
capsulation as a function of coating conditions was explored
(Figure 1). Respective encapsulation eﬃciencies ranged from
16±2% to 53±7% for uncoated and 4.2 kDa PEG-PLL coated
NPs. Statistically significant diﬀerences in encapsulation
eﬃciency from uncoated NPs were observed for NPs with
4.2 kDa PLL (P < 0.005), 4.2 kDa PEG-PLL (P < 0.05), and
24 kDa PEG-PLL (P < 0.05). In almost all cases, the use
of a coating increased the encapsulation eﬃciency. Previous
studies have shown that when PEI was used to stabilize
poly(D,L-lactide-co-glycolide) NPs, the encapsulation eﬃ-
ciency increased from∼43–80% [30]. The cationic polymers
presumably sequester the siRNA from freely diﬀusing during
the fabrication process and help to retain the therapeutic
agent within the NPs. Using PEG-substituted PLL for coating
resulted in increased encapsulation eﬃciency for both 4.2
and 24 kDa PLL systems. Furthermore, the 4.2 kDa PLL
systems, with or without PEG, exhibited nearly double the
encapsulation eﬃciencies of their corresponding 24 kDa PLL
systems (Figure 1). Excluding the 24 kDa PLL systems (which
did not give statistical significance from uncoated NPs), these
results demonstrate that encapsulation eﬃciency can be
controlled through varying PLL size and the incorporation
of PEGylated PLL moieties.
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Figure 1: Encapsulation eﬃciencies of siRNA in various NPs. The
value in parentheses represents the molecular weight of the PLL in
kDa. For statistical comparison via double-sided t-tests, one asterisk
(∗) represents P < 0.05 and data represent average ±1 SD, n > 5.
The siRNA release from the NPs coated with PLL and
PEG-PLL conjugates was monitored over 7 days (Figure 2).
It should be noticed that all systems studied had a minimal
burst eﬀect, which may suggest the incorporation of the
siRNA within the NPs studied. The highest release was
observed in the 4.2 kDa PLL coated NPs, which had a Day
7 release of 93± 1%, while the lowest release was observed in
the 24 kDa PLL coated NPs, with a Day 7 release of 33± 1%.
Despite the similar adsorbed mass incorporated into the
stabilizing layer for both 4.2 and 24 kDa PLLs, the release
profile of siRNA was drastically diﬀerent. This may be an
indication that the 24 kDa PLL coatings form a more stable
NP which may impede both the breakup of the NP and/or
the diﬀusive release of siRNA. However, previous work in our
lab has shown that 4.2 and 24 kDa PLL stabilized NPs yield
similar stabilities at the 0.3mg/mL condition [13]; thus, is it
likely that the diﬀerences observed are most likely due to an
increase in resistance to diﬀusive forces leading to a slower
release profile for the 24 kDa PLL systems.
Interestingly, the eﬀect of incorporating PEG into the
NP coating had a diﬀerent eﬀect upon siRNA release for
4.2 and 24 kDa PLL systems. After 7 days it was observed
that 4.2 kDa coated NPs showed a decrease in siRNA release
from 93 ± 1% to 62 ± 25% (P < 0.05) upon incorporating
PEG, whereas for 24 kDa an increased release from 33 ± 1
to 43 ± 12% occurred upon PEG presence; the latter trend
was not statistically significant. These data may coincide
with the discussion regarding the density of the PEG-PLL
layers highlighted by the ζ-potential studies. Namely, that the
4.2 kDa PLL layer adsorbed more PEG-PLL than the 24 kDa
system, yet had a lower net charge that may suggest a denser
PEG layer that shielded some of the 4.2 kDa PLL charge.
Thus, it is probable that the large 24 kDa PEG-PLL conjugate
was not as able to fill the surface an impede passive siRNA
release as compared to the 4.2 kDa conjugate. Taken together,
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Figure 2: Cumulative siRNA release profile for 4.2 kDa (a) and
24 kDa (b) PLL-based coatings, over seven days. Trend lines are
provided as a guide to the eye only. Data points represent an average
±1 SD, n ≥ 3.
these results indicated that, based upon the presence/absence
of PEG and the size of PLL, siRNA release from BSA NPs
can be controlled over a range of ∼20% to 90% over 7
days. Previously, mPEG-PGLA-PLL coated NPs [31] yielded
a similar release profile, including ∼85% release after 7 days.
Related in vivo work using solid lipid NPs [32] had similar
release profiles except for the fact that they observed an initial
burst release of∼20% that was not observed herein. Through
modifying NP creation parameters in this lipid study, the
overall release could be varied from ∼70–90% over a period
of 7 days. An experiment involving PLGA-PLL NPs (with
adsorbed PEG to improve circulation time) found a plateau
in the release profile at ∼55% after 7 days [33].
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Figure 3: Cell concentrations after exposure to blank NPs ()
and FAM-siRNA-containing NPs (). The value in parentheses
represents the molecular weight of the PLL in kDa. The NPs
coated in PEG-PLL (4 kDa) and containing FAM-siRNA showed the
greatest cell concentrations. Data represent average ±1 SD, n > 5.
3.5. Cellular Uptake. siRNA uptake was investigated in order
to ascertain the delivery potential of the NPs as a function of
coating properties. Flow cytometry was used to detect siRNA
uptake based on NPs containing FAM-labeled siRNA, as well
as the cell counts from the cultures exposed to the NPs.
The latter is representative of cell survival upon incubation
with the NPs containing no siRNA or FAM-labeled siRNA
(Figure 3). Uncoated NPs and NPs coated with 4.2 kDa
PLL had similar cell counts, irrespective of the presence or
absence of encapsulated siRNA. Coating with 24 kDa PLL
caused a dramatic drop in cell numbers, clearly indicating the
toxicity of this type of coating irrespective of the presence or
absence of encapsulated siRNA (Figure 3). After coating with
PEG-substituted PLLs, there was little toxicity for the 24 kDa
PLL for blank NPs and siRNA-containing NPs >20-fold
increase in toxicity. With 4 kDa PLL, using PEG-substituted
PLL gave better cells counts in the absence of siRNA but
somehow reduced cell counts in the presence of siRNA (P <
0.05 between the two groups). No other system showed such
a diﬀerence with and without siRNA (based on paired t-
test). The encapsulated siRNA was nonspecific and was not
expected on its own to cause cell toxicity. It is possible
that it might have resulted in nonspecific eﬀects once inside
the cells since the molecule is highly charged and it might
interact with cationicmolecules critical for cell survival (such
as histones, etc.), ultimately disrupting the normal cellular
physiology. This issue needs to be further explored in future
studies.
The siRNA uptake is summarized in Figure 4 as the
mean uptake (Figure 4(a)) or the percentage of cells positive
for siRNA (Figure 4(b)). The mean fluorescence of the cells
exposed to NPs without FAM-siRNA was not statistically
diﬀerent among the NPs (as expected), and represented
the background readings (i.e., normal autofluorescence).
Compared to uncoated NPs, cells exposed to coated NPs
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Figure 4: Data summarizing the mean uptake and percent cellular
uptake of labeled and unlabeled siRNA. (a) Mean (+1 SD) FAM
fluorescence of the cells exposed to NPs without siRNA () and
with siRNA (). BSA NPs coated with 24 kDa PLL showed the
greatest cellular uptake. (b) Mean (+1 SD) siRNA-positive cells
when the cells were exposed to NPs without siRNA () and with
siRNA (). BSA NPs coated with 24 kDa PLL showed the greatest
value of siRNA-positive cell population. The value in parentheses
represents the molecular weight of the PLL in kDa.
containing FAM-siRNA all had greater fluorescence than the
background (P < 0.01 for NPs coated with 4 kDa PLL, 24 kDa
PLL and 4 kDa PEG-PLL), except the NPs coated with 24 kDa
PEG-PLL. The latter did not show any evidence of increased
uptake based onmean fluorescence of the cells. Although it is
unknown whymodification of the 24 kDa PLL NPs with PEG
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resulted in an insignificant amount of uptake (compared to
controls), it is possible that the large average diameter of
∼800 nm may prohibit cellular uptake. It was clear that the
NPs coated with 24 kDa PLL had the highest cellular delivery
of FAM-labeled siRNA. This was consistent with toxicity
results that indicated highest toxicity (i.e., cell interaction)
with this type of NPs. While the presence of PEG did not
aﬀect uptake with 4.2 kDa PLL, an apparent dramatic eﬀect
of PEG was evident with the 24 kDa PLL. The protein-
repellent properties of PEG presumably prevented binding to
cell surfaces, which is critical for internalization and siRNA
uptake. This result was also in line with toxicity results, where
the cells displayed much more tolerance to 24 kDa PEG-PLL
coated NPs.
Figure 4(b) summarizes that uptake of BSA NPs among
the cell population exposed to the NPs. Note that the uptake
was minimal in the absence of coating (i.e., pure BSA
NPs) and for NPs containing no FAM-labeled siRNA, which
served as the background control (1–3% siRNA-positive cell
population). The only exception to this observation was the
NPs coated with the 24 kDa PLL; a high percentage of cells
(14.4%) became auto-fluorescent that yielded significantly
high proportion of “apparently” siRNA-positive cells. We
previously made such an observation when NPs imparted
certain toxicity on the cells [34]. For example, when cells
are exposed to blank NPs with no reporter genes such as
GFP, they display GFP-like fluorescence (with similar exci-
tation/emission characteristics to FAM) even in the absence
of a reporter gene. It is not surprising that the most toxic
formulation in this study behaved in this way as well.
With NPs coated by 4.2 kDa PLL and 4.2 kDa PEG-
PLL, ∼16 and 17% of the cells, respectively, yielded siRNA-
positive cells, clearly indicating the beneficial eﬀect of this
coating on the cellular delivery of the NPs. With NPs coated
by 24 kDa PLL, 62.2% of the cells yielded siRNA-positive
cells, but using the same MW PLL with PEG substitution
abolished the uptake totals (note the lack of diﬀerence in
cell uptake for between siRNA-positive and siRNA-negative
NPs). Considering the auto-fluorescence obtained in the cells
exposed the 24 kDa PLL coated NPs, we expect the uptake
to be closer to ∼48% in this case. PEG obviously plays a
significant role in this case, preventing the uptake of the
NPs. This is in line with previous protein adsorption results,
which indicated relatively less binding of plasma proteins to
the NPs. It must be noted that the uptake values reported
among the cell population should be considered as a relative
measure to compare diﬀerent NP formulations and not taken
at absolute values. It is possible to significantly alter the
measured values depending on the siRNA loading in NPs;
with higher fluorescing NPs, higher rates of uptake could be
obtained for the same formulations.
4. Conclusions
The stabilizing coating used on BSA NPs was expected to
have significant implications on the physical characteristics
of the formed NPs, blood plasma interactions, siRNA
encapsulation, and cellular uptake. It was observed that the
use of PEG increased average NP size and polymer coating on
the NPs. In addition, PEG coatings were found to decrease
nonspecific protein adsorption from human plasma as well
as decrease the cytotoxicity of certain NPs (i.e., ones coated
with highly toxic 24 kDa PLL). This result was likely not due
to size, but rather attributed to inherently higher toxicity of
the high MW PLL. Although an extensive array of adsorbed
proteins was found on the NP surfaces, proteins for both
passivating the NPs as well as activating the foreign body
reactions were noted. The benefit of a PEGylated NPs was
not clear in this respect and further evaluation (in vitro or
in vivo) will be necessary to fully reveal the biocompatibility
of the NPs. For the NPs coated with 4.2 kDa PLL, PEG also
increased the siRNA encapsulation eﬃciency, maintained a
similar cellular uptake, and delayed siRNA release over a
period of 7 days. These desirable results suggest that NP
engineering could be possible by controlling PLL size and
the use of PEG to prevent the removal from the blood-
stream without hindering the eﬃciency of drug delivery.
It is thought that the fundamental knowledge acquired in
this study will further the design of coating strategies for
controlling the formation and biological interactions of BSA
NPs in circulation for the express purpose of delivering drugs
via systemic administration.
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